Therapeutic drug monitoring in pregnant and postpartum women: recommendations for SSRIs, lamotrigine, and lithium
Department of Psychiatry
Anticonvulsants; Antimanic Agents; Depressive Disorder; Drug Monitoring; Epilepsy; Female; Humans; Lithium Compounds; Postpartum Period; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications; Serotonin Uptake Inhibitors; Triazines
Recently, guidelines for antenatal management of depression were published.1 Psychotherapy alone may be an appropriate treatment for some women, while psychopharmacotherapy may be indicated in others. Use of psychopharmacotherapy during pregnancy and the postpartum involves complex clinical decisions based on the risks and benefits and alternatives to medications. The aim of effective treatment is to minimize maternal and fetal exposure to psychiatric illness by optimally treating it with the minimum effective dose regimen. One variable that complicates psychopharmacotherapy is that dosing often requires adjustment to maintain therapeutic effects, particularly in late pregnancy. The current article focuses on those factors that affect dosing in pregnancy.
Deligiannidis KM. Therapeutic drug monitoring in pregnant and postpartum women: Recommendations for SSRIs, lamotrigine and lithium. Journal of Clinical Psychiatry 71(5):649-650, 2010.
The Journal of clinical psychiatry
Deligiannidis KM. (2010). Therapeutic drug monitoring in pregnant and postpartum women: recommendations for SSRIs, lamotrigine, and lithium. Psychiatry Publications. Retrieved from https://escholarship.umassmed.edu/psych_pp/331